- Spectral Medical’s (EDT) wholly-owned subsidiary Dialco Medical, announced that ARC Dialysis has selected the SAMI device for inpatient dialysis services
- SAMI provides ARC Dialysis with an alternative equipment option to hospital customers who are looking to outsource dialysis treatments
- ARC Dialysis is the largest inpatient dialysis provider in South Florida
- Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin (“PMX”)
- Spectral Medical Inc. (EDT) was up 6.78 per cent, trading at C$0.315 per share as of 2:05 pm ET
Spectral Medical’s (EDT) wholly-owned subsidiary Dialco Medical announced that ARC Dialysis has selected the SAMI device for inpatient dialysis services.
SAMI provides ARC Dialysis with an alternative equipment option for hospital customers looking to outsource dialysis treatments. This latest agreement follows a clinical evaluation performed by ARC Dialysis in 2021.
ARC Dialysis is the largest inpatient dialysis provider in South Florida. It specializes in acute, outpatient and in-home therapies. ARC operates twelve centers, offering in-center dialysis, and home and peritoneal dialysis modalities. ARC also operates through a network of health systems, hospitals, skilled nursing and rehab facilities.
Sam Amory, President of Dialco, commented on the news.
“We are honored to have the SAMI device selected by ARC Dialysis following an extensive clinical evaluation of the technology. We believe this selection of SAMI over competing CRRT systems reflects the workflow, economic and clinical benefits of our device. Specifically, SAMI reduces the burden on staff, due to the rapid setup, user-friendly interface, safety sensors and more.”
Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product to treat patients with septic shock, Toraymyxin (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. It is guided by the company’s Endotoxin Activity Assay (EAA), the only FDA cleared diagnostic for the risk of developing sepsis.
Spectral, through its wholly-owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI targets the acute RRT market, while DIMI targets the chronic RRT market.
Spectral Medical Inc. (EDT) was up 6.78 per cent, trading at C$0.315 per share as of 2:05 pm ET.
